Despite showing promise, rapalog monotherapy has been proven mostly insufficient in causing tumor regression, with notable exceptions of tumors showing mutations in mTOR itself, LOF mutations in TSC1 or TSC2 [55,56,57,58,59]. This evidence concerns the gene TSC2 and neoplasm.